key: cord-0072668-c48fp5zu authors: Tursi, Antonio; Nenna, Rosanna title: COVID-19 as a Trigger for De Novo Crohn’s Disease date: 2021-11-24 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izab298 sha: 77e61f8a37cdd31b78e3d32eb692b43aeb31ef0c doc_id: 72668 cord_uid: c48fp5zu A 47-year-old woman developed a de novo occurrence of Crohn’s disease after coronavirus disease 2019. This is an unusual occurrence and suggests that severe acute respiratory syndrome coronavirus 2 could trigger inflammatory bowel disease in predisposed people. To the Editors: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a significant impact on the management of all diseases, and inflammatory bowel disease (IBD) is no exception. 1,2 While the clinical picture of IBD during coronavirus disease 2019 (COVID-19) becomes clearer, 1 less is known about the impact of COVID-19 as a potential risk factor for IBD occurrence. In May 2021, a 47-year-old woman experienced weakness, myalgia, and diarrhea, with up to 5 bowel movements per day, without the presence of a cough or breathlessness. As symptoms persisted for 5 days, a nasopharyngeal swab was performed, resulting in a positive result for SARS-CoV-2. Thoracic radiographs and laboratory tests were unremarkable, except for a raised C-reactive protein (CRP) of 12 mg/ dL. She received paracetamol and was advised to self-isolate. Weakness and myalgia disappeared within a week, and her diarrhea also improved. However, during the following 4 months, she had recurrent episodes of diarrhea despite monthly treatment with probiotics. At the beginning of September 2021, she developed frequent and large-volume diarrhea episodes of up to 10 bowel movements per day. Laboratory tests showed hemoglobin 10.5 g/dL, erythrocyte sedimentation rate 78 mm/h, CRP 39 mg/dL, and fecal calprotectin 290 mg/g. Stool microscopy culture did not reveal any pathogens, and the nasopharyngeal swab was negative. Ileocolonoscopy showed multiple erosions located in the terminal ileum ( Figure 1A ). Histopathology showed focal architectural distortion and dense lymphoplasmacytic and eosinophils infiltration through the lamina propria ( Figure 1B Letter to the Editor 2 segmental wall thickening (8 mm) of the terminal ileum, with mucosal hyperenhancement, mesenteric vascularity, and lymphoadenomegaly. The diagnosis of de novo Crohn's disease (CD) was made. Oral budesonide 9 mg/kg was prescribed for 8 weeks, and diarrheal episodes improved over the following 3 weeks. The patient is currently in clinical remission, and follow-up laboratory tests showed hemoglobin 12.1 g/d, erythrocyte sedimentation rate 22 mm/h, CRP 9 mg/dL, and fecal calprotectin 112 mg/g. There are established links between enteric infection-related dysbiosis and the future development of IBD. 3 After binding to the angiotensin-converting enzyme 2 receptor on the intestinal epithelial cells, SARS-CoV-2 enters the cell, causing enhanced tumor necrosis factor α production. 4 A T helper cell 17 cytokine storm has been identified in COVID-19, 5 similar to that seen in CD. Therefore, it is hypothesized that this immune dysregulation with related intestinal inflammation due to SARS-CoV-2 might create a favorable milieu that can trigger the onset of CD in susceptible individuals. A.T. and R.N. planned and conducted the study; A.T. and R.N. collected data; A.T. interpreted data and drafted the manuscript; A.T. and R.N. approved the final draft submitted. No financial support was obtained for this study. Epidemiology and the impact of therapies on the outcome of COVID-19 in patients with inflammatory bowel disease Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology Infectious gastroenteritis and risk of developing inflammatory bowel disease Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib The authors declare no conflict of interest.